Treatment with the anti-diabetic drug alogliptin does not increase CV risk in patients with ACS

Patients with type 2 diabetes and high cardiovascular risk due to recent acute coronary syndromes had similar rates of cardiovascular events when treated with the anti-diabetic agent alogliptin compared to placebo according to results of the Examination of Cardiovascular Outcomes with Alogliptin versus Standard of Care (EXAMINE) trial presented at the European Society of Cardiology Congress.

"Compared with placebo, treatment with alogliptin resulted in similar rates of the primary endpoint, which was a composite of cardiovascular death, , and stroke ," said the chair of the study's steering committee William B. White, MD, from the University of Connecticut School of Medicine in Farmington, Connecticut, USA.

"The findings could guide clinicians to choose among the many anti-diabetic agents available when treating patients with type 2 diabetes and very high cardiovascular risk," he suggested.

EXAMINE, designed as a non-inferiority trial, was undertaken to satisfy U.S. Food and Drug Administration requirements that new be subjected to studies to rule out cardiovascular risk.

"It represents the first cardiovascular safety trial of an anti-diabetic drug in patients with . Hence, for those who are likely candidates for the drug in clinical practice with elevated CV risk, including those with a recent acute coronary syndrome, it is reassuring that alogliptin does not increase or mortality," noted Dr. White.

"However, EXAMINE does not rule out longer-term benefits or risks of alogliptin with respect to cardiovascular end points as the median duration of the trial was approximately 18 months," he added.

The trial recruited 5,380 patients from 898 centers in 49 countries and randomized them to receive alogliptin or placebo, administered in a double-blind fashion along with standard-of-care treatment for and .

Due to its renal clearance, alogliptin dosing was modified according to kidney function, with 71.4% of patients receiving 25 mg, 25.7% receiving 12.5 mg, and 2.9% receiving 6.25 mg daily.

After a median follow-up of 18 months, and up to 40 months, the primary endpoint, which was a composite of , myocardial infarction, and stroke had occurred at a similar rate in alogliptin and placebo-treated patients (11.3% vs 11.8% respectively; P <0.001 for non-inferiority).

As would be expected with an antihyperglycemic agent, end-of-study glycated hemoglobin levels were significantly lower in patients on alogliptin than placebo with a mean change from baseline of -0.33% and +0.03% respectively.

Incidences of hypoglycemia, malignancy, pancreatitis, and dialysis were similar for both groups.

To date, research has yet to identify a diabetes drug that is not only safe but actually beneficial to the heart – an important issue for diabetic patients who are at high risk for cardiovascular problems.

The EXAMINE trial satisfied FDA requirements to show cardiovascular safety but built into the trial design, as a secondary objective, was an exploration for cardiac benefits which were not found.

"There is a need for safe glucose lowering therapies in patients with diabetes who are at an elevated risk for cardiovascular disease," he added. "Given the EXAMINE study design and high risk patient population evaluated, these results provide key insights to clinicians treating diabetes patients with cardiovascular disease."

add to favorites email to friend print save as pdf

Related Stories

n-3 fatty acids no benefit for high-risk cardio patients

May 09, 2013

(HealthDay)—For patients with multiple cardiovascular risk factors or atherosclerotic vascular disease who have not had a myocardial infarction, daily treatment with n-3 fatty acids does not reduce cardiovascular ...

Median follow-up results from the ALTITUDE study

Aug 27, 2012

Preliminary results from the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) do not support administration of aliskiren on top of standard therapy with renin-angiotensin-aldosterone system (RAAS) ...

Statins reduce CV events in CAD patients with very low LDL-C

Sep 01, 2013

Aggressive treatment with statins reduces the risk of subsequent cardiovascular events in patients with coronary artery disease even if they have very low LDL cholesterol levels, reveals research presented at ESC Congress ...

Recommended for you

Vitamin D does not stop heart attack or stroke

19 hours ago

(Medical Xpress)—Taking vitamin D tablets cannot ward off heart attacks or stroke according to a new study from researchers at the University of East Anglia (UEA) published in the American Journal of Cl ...

New guidance on antithrombotic use in AF patients with ACS

20 hours ago

A new European joint consensus document on the use of antithrombotic drugs, including the non-vitamin K antagonist oral anticoagulants (NOACs), in patients with atrial fibrillation (AF) presenting with an acute coronary syndrome ...

USPSTF recommends counseling for adults at risk for CVD

Aug 26, 2014

(HealthDay)—The U.S. Preventive Services Task Force (USPSTF) recommends offering or referring overweight and obese adults with cardiovascular disease risk factors to intensive behavioral counseling. These ...

User comments